Part of a series of events to support the growth and success of the life science organisations clustered around Charnwood Campus Science, Innovation and Technology Park Business leaders, entrepreneurs, innovators and stakeholders gathered at Charnwood Campus to celebrate our inno...Read more
£54m construction project in Loughborough creates flexible facility for a growing CRO
Charnwood Campus has recommissioned its world-class synthetic and chemistry research facility to the highest standard to cater to the needs of its newest occupier and leading pre-clinical discovery contract research organisation (CRO) Charnwood Molecular, in a £54m construction project.
The three-storey, state-of-the-art synthetic and chemistry research facility has been fully modernised by engineering firm Couch Perry Wilkes, following the delivery of a number of complex projects for Charnwood Campus including 33,000sqft of laboratory space for the UK Department of Health and Social Care’s Lighthouse Lab.
Part-funded (£3.5m) by the Enterprise Zone reinvestment fund facilitated through co-operation with the Leicester and Leicestershire Enterprise Partnership (LLEP) and Charnwood Borough Council (CBC), the new laboratories will provide substantial capacity for future growth and expansion of Charnwood Molecular’s medicinal chemistry and process research teams, as well as facilitate the addition of drug discovery service lines.
Through a competitive tender process, Charnwood Campus appointed CPW as the design engineers, Leicester-based Mellor Bromley as its contractors and Loughborough firm Addison Hunt to undertake project management and administration and quantity surveying roles.
Charnwood Campus Commercial Director Gosia Khrais says: “It is a great pleasure to welcome Charnwood Molecular as a new occupier here. The project is a recommissioning of an existing facility to meet the bespoke requirements of this fantastic CRO, and includes construction of a car park with EV charging points.
“Delivering the greatest value to organisations that relocate to Charnwood Campus is at the core of everything we do, and partners like Couch Perry Wilkes enable us to do just that.
“The project is part-funded by the LLEP following successful negotiation and drafting of the reinvestment mechanisms with both the LLEP and Charnwood Borough Council (CBC). This close co-operation is playing an instrumental role in fast-tracking site development, including this project, which is fuelling job creation in the local area as well as the wider region. We are lucky to have a forward-thinking and business- and community-orientated council, as well as an open-minded and ambitious LLEP. Over the years, we have received a lot of positive feedback from local businesses and Loughborough residents. We are very humbled and grateful for that support, and we will continue to work tirelessly to facilitate job creation, accelerate economic growth and play our part in the COVID recovery effort.”
Carl Hubbard, Associate Director at Couch Perry Wilkes said: “It is a privilege to be involved in such a prestigious project to bring a state-of-the-art building back to life to support the development and growth of its ambitious new occupier, following Couch Perry Wilkes’ previous successful delivery of the Lighthouse Lab facility at Charnwood Campus. The works have extended the life and improved the building’s efficiencies and provide Charnwood Molecular with a future-proof base in which expand its team and service lines.”
Dimian Elouadihi, Director at Mellor Bromley said: “We were excited that Mellor Bromley was awarded the project following a competitive tender process. We are acting as principal contractor for the works, employed directly by Charnwood Campus. The construction works started in April 2021 and we look forward to successfully completing the project for Charnwood Campus later this year.”
Simon Collin, Equity Director at Addison Hunt added: “We are pleased to be working with Charnwood Campus in providing project management, cost management and principal designer services on this prestigious project for end-user Charnwood Molecular. This is our first project on site with Charnwood Campus and we continue to build our relationship to become its trusted partner.”
Kevin Harris, Chair of the LLEP Board of Directors said: “It is great that we have been able to help fund this project with a £3.5 million grant from our Enterprise Zone Investment Fund. Charnwood Campus is at the forefront of life sciences research, which we are very proud to specialise in at our Enterprise Zone here in Leicestershire. The grant has enabled fast tracking of the site development and will help create more highly-skilled jobs in our region.”
Cllr Jonathan Morgan, Leader of Charnwood Borough Council, said: “Charnwood’s reputation for growth and innovation continues to flourish and this is the latest example of significant inward investment to create high-skilled jobs in the area. I would like to congratulate Charnwood Campus and everyone involved on another fantastic project and wish Charnwood Molecular all the very best for the future.”
Jane Hunt, MP for Loughborough adds: “I am delighted to welcome Charnwood Molecular to our Life Science Opportunity Zone at Charnwood Campus. As you can tell by their name, the company has a strong association with Loughborough having originated in the town many years ago. I am thrilled that they will be coming to Charnwood Campus, a jewel in the Loughborough crown. The move will bring business, jobs and growth to our area and will help to create a cluster of science-based excellence that Loughborough has become renowned for in recent years.”
Leading UK pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, Charnwood Molecular, has joined Charnwood Campus and expanded its operations in a deal expected to support the growth of its contract research services.
Charnwood Molecular continues to build upon its foundation in medicinal chemistry, scale-up chemistry and custom synthesis provision, evolving its business strategy to deliver increasingly high-tech and high-value research capabilities. In order to enable and enhance its ambitious expansion plans, Charnwood Molecular partnered with Synova, a leading and award-winning European private equity fund, who have made a significant investment into the business. The deal has provided the company with additional capital to support its future development and growth, including the introduction of additional senior leadership team members into the business.
Charnwood Molecular’s ambitious growth plans now see the company becoming the sole occupier of a substantial three-storey, state-of-the-art laboratory facility at Charnwood Campus. Recently designated a Life Sciences Opportunity Zone, Charnwood Campus provides an environment to inspire discovery, encourage collaboration and accelerate business growth within the medtech and biopharma industries.
Charnwood Molecular has seen significant expansion of its global client base in recent years and this latest physical expansion of the business will support its growth plan across a wide range of contract research services: from medicinal chemistry, chemical development and early process research through to developing a suite of complementary services in order to provide a holistic pre-clinical discovery portfolio to its international client base.
Commenting, Gosia Khrais, Commercial and Marketing Director at Charnwood Campus, said: “It is a great pleasure to welcome Charnwood Molecular as a new occupier here. This fantastic CRO with ambitious growth plans will cement life sciences as a priority sector in the region, create jobs and help us grow our local economy. It is really great news for Loughborough.”
CEO of Charnwood Molecular, Steve Allin said: “The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines.”
John Handley, Managing Director of Charnwood Molecular, added: “Our expansion plans for the business are now coming to fruition. From hiring significant numbers of new scientists at both of our existing research sites, through to a doubling of our business development team and now adding much larger bespoke facilities, we are looking to the future to make Charnwood Molecular a very major player in the discovery CRO marketplace.”
Charnwood Campus still has availability of laboratory and office space as well as development land. Please contact our team at: firstname.lastname@example.org for more details.
Global contract development and manufacturing organisation (CDMO) Kindeva Drug Delivery has expanded its operations at Charnwood Campus, in a deal expected to support Kindeva’s continued growth in the UK.
The US-headquartered company will take over a state-of-the-art research and development facility at Charnwood Campus, and a further 20,000 square feet of office space at the site.
Formerly 3M Drug Delivery Systems, Kindeva specialises in solving complex drug delivery and combination product challenges for its pharmaceutical and biotechnology customers, and currently employs over 500 staff in the UK across its two sites at Charnwood Campus, its Loughborough plant, and its Clitheroe plant. The company formulates, develops, and manufactures therapies used by patients suffering from serious health conditions including respiratory illnesses, central nervous system disorders, and cancer.
Charnwood Campus is now home to four blue-chip organisations including Almac, 3M, Kindeva, and global diagnostics company PerkinElmer.
Commenting on the deal, Gosia Khrais, Charnwood Campus Commercial Director says: “Kindeva’s expansion is great news for both the Charnwood site and the local area, with the company’s ambitious growth plans set to create new office-based roles as well as safeguard hundreds of highly valuable scientific jobs in Loughborough and the East Midlands.
“The deal is another significant milestone in our long-term development plan and further reinforces the East Midlands’ and Loughborough’s reputation for outstanding pharmaceutical research and development.
“With a strong legacy of more than 60 years of pharmaceutical innovation, Kindeva is a well-established business and a significant player in the global drug development and delivery pharmaceutical industry,” she adds. “We feel honoured the company has chosen to expand its operations at Charnwood as well as support us in playing our part in the UK’s economic recovery.”
“As a growing CDMO and life sciences company, Kindeva thrives on our base of well-trained, highly-qualified leaders in scientific research and development,” said Aaron Mann, CEO of Kindeva Drug Delivery. “The Charnwood campus provides a state-of-the-art laboratory design to support our industry-leading talent. Importantly, the proximity to general management offices promotes cross-functional collaboration between our R&D team and other areas of the business, enabling consistent feedback of customer needs and insights into our R&D activities.”
Councillor Jonathan Morgan, Leader of Charnwood Borough Council, said: “This is excellent new for Charnwood Campus and the borough. I am delighted that not only are a significant number of jobs being safeguarded, but more are being created, which is important as we look to the future and recovery from the pandemic. One of the Council’s top priorities is to support the growth of the local economy and sites like Charnwood Campus will play a key role in that growth.”
Charnwood Campus is the first and only Life Sciences Opportunity Zone in the UK and part of the Loughborough and Leicester Science and Innovation Enterprise Zone.
Charnwood Campus has recommissioned its world-class synthetic and chemistry research facility to the highest standard to cater to the needs of its newest occupier and leading pre-clinical discovery contract research organisation (CRO) Charnwood Molecular, in a £54m construction project. ...Read more